Beranda › Leukemia Mieloid Akut › Tennessee › Knoxville
Uji klinis Leukemia Mieloid Akut di Knoxville, TN
4 studi untuk Leukemia Mieloid Akut mencari peserta di lokasi sekitar Knoxville (dalam radius sekitar 30 mil). Buka studi untuk melihat kriteria peserta dan cara menghubungi tim studi.
Teks studi resmi (Bahasa Inggris)
Merekrut peserta untuk studi di sini? Tampilkan di bagian atas halaman ini — $99 selama 30 hari →
A Study of Bleximenib, Venetoclax and Azacitidine For Treatment of Participants With Newly Diagnosed Acute Myeloid Leukemia (AML)
Menerima pesertaFase 3
- University of Tennessee, Knoxville
A Study to Compare Standard Chemotherapy to Therapy With CPX-351 and/or Gilteritinib for Patients With Newly Diagnosed AML With or Without FLT3 Mutations
Menerima pesertaFase 3
- East Tennessee Childrens Hospital, Knoxville
Xylitol Dental Wipes for the Reduction of Bloodstream Infection Risk in Children With Acute Myeloid Leukemia
Menerima pesertaFase 3
- East Tennessee Childrens Hospital, Knoxville
The Pediatric Acute Leukemia (PedAL) Screening Trial - A Study to Test Bone Marrow and Blood in Children With Leukemia That Has Come Back After Treatment or Is Difficult to Treat - A Leukemia & Lymphoma Society and Children's Oncology Group Study
Menerima pesertaFase 1/2
- East Tennessee Childrens Hospital, Knoxville
Uji klinis Leukemia Mieloid Akut di kota lain
- Houston, TX85 studi
- New York City, NY51 studi
- Boston, MA44 studi
- Seattle, WA41 studi
- Baldwin Park, CA40 studi
- Columbus, OH35 studi
- Philadelphia, PA34 studi
- Durham, NC33 studi
- Atlanta, GA31 studi
- Tampa, FL29 studi
- Chicago, IL26 studi
- Portland, OR25 studi
Studi lain di Knoxville
- Kanker Paru Non-Sel Kecil14 studi
- Obesitas10 studi
- Kanker Paru10 studi
- Kanker Payudara9 studi
- Kanker (semua jenis)8 studi
- Kelebihan Berat Badan7 studi
- Gagal Jantung7 studi
- Kanker Metastatik7 studi
- Penyakit Kardiovaskular6 studi
- Melanoma5 studi
- Diabetes Tipe 25 studi
- Tekanan Darah Tinggi5 studi
Dari ClinicalTrials.gov, data diambil 6 Okt 2026. Setiap studi menetapkan kriteria kelayakannya sendiri; tim studi yang menentukan siapa yang bisa bergabung.